Recurrent leishmaniasis in people with HIV
Part of Immune system & allergy, Infections clinical trials.
This study looks at better ways to treat visceral leishmaniasis (a serious parasitic infection) when it comes back in people who also have HIV. It may help find a plan that works longer and reduces the chance of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have visceral leishmaniasis (confirmed by a test from your spleen or bone marrow)
- You are also infected with HIV (diagnosed now or in the past)
- You are at least 18 years old
- You are willing to take part in the study and come for follow-up visits
- You are able to give your informed consent and participate physically and mentally
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a prognostic score to predict whether visceral leishmaniasis (VL) will come back after treatment. If you qualify, your information may help doctors estimate relapse risk and plan follow-up more safely.
This trial uses a special blood-filtering procedure (leukapheresis) along with blood tests to better understand how HIV affects the body. It may help researchers learn more about HIV “pathogenesis,” which means what drives disease in different people.
This study measures how much HIV is in your blood and lymph node tissue. If you qualify, you would also allow blood and other tests (including genetic and hepatitis screening), which may help researchers better understand how HIV affects the body.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study tests whether giving people with HIV a liver from an HIV-positive donor is safe and works well. It looks at infections, cancer risks, and long-term health after transplant.
This study tests how well researchers can track HIV-related health and immune changes over time by collecting blood and other samples. It may help you and your care team by creating detailed monitoring, even if your HIV diagnosis is new or still being evaluated.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.